Poland· PL-100516139
Capvaxive
A pneumokokken, gereinigtes polysaccharid-antigen, konjugiert product containing szczepionka przeciw pneumokokom, polisacharydowa, skoniugowana (21-walentna), registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pneumokokken, gereinigtes polysaccharid-antigen, konjugiert is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AL02 (pneumokokken, gereinigtes polysaccharid-antigen, konjugiert), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Pneumokokken, gereinigtes polysaccharid-antigen, konjugiert · ATC J07AL02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Szczepionka przeciw pneumokokom, polisacharydowa, skoniugowana (21-walentna)
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- J07AL02
- ATC class
- Pneumokokken, gereinigtes Polysaccharid-Antigen, konjugiert
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin00191778024852
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AL02
Pneumokokken, gereinigtes polysaccharid-antigen, konjugiert, as other registers publish it.
- SwitzerlandCapvaxive
- IcelandCapvaxiveMerck Sharp & Dohme B.V.
- NorwayCapvaxiveMerck Sharp & Dohme B.V.
- SwitzerlandCapvaxive
- BelgiumCapvaxiveMerck Sharp & Dohme
- CzechiaCAPVAXIVEMerck Sharp & Dohme B.V., Haarlem
- CzechiaCAPVAXIVEMerck Sharp & Dohme B.V., Haarlem
- CzechiaCAPVAXIVEMerck Sharp & Dohme B.V., Haarlem
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3e5b03c3-57a8-49d8-9d02-239384b0de64 GET /v1/drugs/3e5b03c3-57a8-49d8-9d02-239384b0de64?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
"source": "urpl",
"strength": "1 dawka 0,5 ml",
"packaging": "Rp ¦ EU/1/25/1913/001 ¦ 161370\n1 amp.-strzyk. 0,5 ml bez igły\n00191778024852 ¦ Rp ¦ EU/1/25/1913/002 ¦ 161371\n1 amp.-strzyk. 0,5 ml ¦ 1 igła \nRp ¦ EU/1/25/1913/003 ¦ 161372\n1 amp.-strzyk. 0,5 ml ¦ 2 igły \nRp ¦ EU/1/25/1913/004 ¦ 161373\n10 amp.-strzyk. 0,5 ml bez igły\nRp ¦ EU/1/25/1913/005 ¦ 161374\n10 amp.-strzyk. 0,5 ml ¦ 10 igieł \nRp ¦ EU/1/25/1913/006 ¦ 161375\n10 amp.-strzyk. 0,5 ml ¦ 20 igieł",
"substance": "Polisacharyd pneumokokowy serotyp 3 skoniugowany z białkiem nośnikowym CRM197 4 mcg + Polisacharyd pneumokokowy serotyp 6A skoniugowany z białkiem nośnikowym CRM197 4 mcg + Polisacharyd pneumokokowy serotyp 7F skoniugowany z białkiem nośnikowym CRM197 4 mcg + Polisacharyd pneumokokowy z deOAc15B (de-O-acetylowany serotyp 15B) skoniugowany z białkiem nośnikowym CRM197 4 mcg",
"common_name": "Szczepionka przeciw pneumokokom, polisacharydowa, skoniugowana (21-walentna)",
"pl_product_id": "100516139",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about pneumokokken, gereinigtes polysaccharid-antigen, konjugiert.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.